Central Nervous System Penetration and Plasma Pharmacokinetics of Telavancin in Critically Ill Patients

Grants and Contracts Details

StatusActive
Effective start/end date10/11/2310/11/25

Funding

  • Cumberland Pharmaceuticals Inc: $6,378.00